A China-based biotech was at the pivotal stage of development of an asset targeting oncology.
Strong mid-clinical stage data had been generated in China.
The biotech had devised a global development plan for the asset but that plan would have resulted in an undesirable second-to-market position.
Conducted a comprehensive situation assessment from an investor’s and potential partner’s point of view.
Holistically re-designed the clinical development plan.
The improvements enabled the biotech to leapfrog their competitor.
Implemented check-points to reduce capital-at-risk and enhance agility.
The actions and measures implemented by Treehill led to a strongly-enhanced appeal of the asset to potential investors. This laid the essential foundation for an anchor investment necessary to carry the program forward in a NewCo.
Conducted a comprehensive situation assessment from an investor’s and potential partner’s point of view.
Holistically re-designed the clinical development plan.
Holistically re-designed the clinical development plan.
Holistically re-designed the clinical development plan.
Conducted a comprehensive situation assessment from an investor’s and potential partner’s point of view.
Holistically re-designed the clinical development plan.
The improvements enabled the biotech to leapfrog their competitor.
Implemented check-points to reduce capital-at-risk and enhance agility.
